Huayu Biopharma Completes Series B Funding

The company successfully completed Series B funding of 500 million RMB.

Hangzhou Huayu Biopharma Co., Ltd. recently announced the completion of Series B funding of 500 million RMB, led by several renowned investment institutions. The funds will be used to accelerate clinical advancement of core pipelines and industrial base construction.